Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions
Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of f...
Saved in:
Published in | Molecular pharmaceutics Vol. 18; no. 11; pp. 4131 - 4139 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
01.11.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 1543-8384 1543-8392 1543-8392 |
DOI | 10.1021/acs.molpharmaceut.1c00543 |
Cover
Loading…
Abstract | Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, k D, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation. |
---|---|
AbstractList | Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, kD, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation.Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, kD, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation. Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, k D, percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation. Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram quantities of material. Here, we present a simple, versatile method that provides valuable information to guide the identification and comparison of formulation conditions for, in principle, any biopharmaceutical drug. The subject protein is incubated with a designed synthetic peptide microarray; the extent of binding to each peptide is dependent on the solution conditions. The array is washed, and the adhesion of the subject protein is detected using a secondary antibody. We exemplify the method using a well-characterized human single-chain Fv and a selection of human monoclonal antibodies. Correlations of peptide adhesion profiles can be used to establish quantitative relationships between different solution conditions, allowing subgrouping into dendrograms. Multidimensional reduction methods, such as t-distributed stochastic neighbor embedding, can be applied to compare how different monoclonals vary in their adhesion properties under different solution conditions. Finally, we screened peptide binding profiles using a selection of monoclonal antibodies for which a range of biophysical measurements were available under specified buffer conditions. We used a neural network method to train the data against aggregation temperature, , percentage recovery after incubation at 25 °C, and melting temperature. The results demonstrate that peptide binding profiles can indeed be effectively trained on these indicators of protein stability and self-association in solution. The method opens up multiple possibilities for the application of machine learning methods in therapeutic protein formulation. |
Author | Edwards, John Austerberry, James Eyes, Tim Derrick, Jeremy P |
AuthorAffiliation | School of Biological Sciences, Faculty of Biology, Medicine, and Health |
AuthorAffiliation_xml | – name: School of Biological Sciences, Faculty of Biology, Medicine, and Health |
Author_xml | – sequence: 1 givenname: James surname: Austerberry fullname: Austerberry, James – sequence: 2 givenname: John surname: Edwards fullname: Edwards, John – sequence: 3 givenname: Tim surname: Eyes fullname: Eyes, Tim – sequence: 4 givenname: Jeremy P orcidid: 0000-0002-4350-5354 surname: Derrick fullname: Derrick, Jeremy P email: Jeremy.Derrick@manchester.ac.uk |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34658237$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkctOwzAQRS1URB_wC8js2LT4kcTOsqooVCqii7KOHNuhrhI72AlS_x5XLZXYsboz8rmj8dwxGFhnNQAPGM0wIvhJyDBrXN3uhG-E1H03wxKhNKFXYISjTDnNyeBS82QIxiHsESJJSugNGNIkSzmhbATqj6Chq-BGt51RGr4Z6Z3wXhwCrJyHSxE6KKyCKxvbRnTmW8ONd5Wpjf08Orc77UUblzASzm1nSqcOcBnZvo60s3DhrDLHKtyC60rUQd-ddQK2y-ft4nW6fn9ZLebrqaCIdVNVMcKQzJTEWHOkMsIIT0qJBeUZp2mmMsHjO5NZVZUsL_M8EanKE5xqxhidgMfT2Na7r16HrmhMkLquhdWuDwVJOaUE8ygTcH9G-7LRqmi9aYQ_FL8HikB-AuJZQvC6uiAYFccwihhG8SeM4hxG9KYn7xHZu97b-Ol_-H4AW1uV-A |
Cites_doi | 10.1038/s41573-019-0028-1 10.1021/acs.biochem.9b00367 10.1016/j.jpba.2020.113703 10.1002/bit.22702 10.1073/pnas.1616408114 10.1016/j.ejpb.2017.01.019 10.1093/toxsci/kfw121 10.1021/acs.molpharmaceut.9b00852 10.1371/journal.pone.0168453 10.1073/pnas.1810576116 10.1093/bioinformatics/btl117 10.1038/nbt1000 10.1016/j.molimm.2018.11.020 10.1007/s11095-008-9737-6 10.3389/fimmu.2016.00394 10.1080/19420862.2020.1743053 |
ContentType | Journal Article |
Copyright | 2021 American Chemical Society |
Copyright_xml | – notice: 2021 American Chemical Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1021/acs.molpharmaceut.1c00543 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1543-8392 |
EndPage | 4139 |
ExternalDocumentID | 34658237 10_1021_acs_molpharmaceut_1c00543 c453877971 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Biotechnology and Biological Sciences Research Council grantid: BB/L006391/1 – fundername: Biotechnology and Biological Sciences Research Council grantid: BB/M006913/1 |
GroupedDBID | - 123 4.4 53G 55A 5VS 7~N AABXI ABFRP ABMVS ABUCX ACGFS ACS AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED F5P GGK GNL H~9 IH9 JG P2P RNS ROL UI2 VF5 VG9 W1F X --- -~X AAYXX ABBLG ABJNI ABLBI ABQRX ADHLV BAANH CITATION CUPRZ ED~ JG~ CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-a307t-df7270c6dc11e80d627284bc1a3868356d6a80c67c6ffb79b994a5d9415e7773 |
IEDL.DBID | ACS |
ISSN | 1543-8384 1543-8392 |
IngestDate | Fri Jul 11 01:27:05 EDT 2025 Thu Jan 02 22:55:12 EST 2025 Tue Jul 01 04:33:51 EDT 2025 Wed Nov 03 07:36:19 EDT 2021 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | formulation peptide microarray biopharmaceutical monoclonal antibody |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a307t-df7270c6dc11e80d627284bc1a3868356d6a80c67c6ffb79b994a5d9415e7773 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4350-5354 |
PMID | 34658237 |
PQID | 2583321858 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2583321858 pubmed_primary_34658237 crossref_primary_10_1021_acs_molpharmaceut_1c00543 acs_journals_10_1021_acs_molpharmaceut_1c00543 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20211101 2021-11-01 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 20211101 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmaceutics |
PublicationTitleAlternate | Mol. Pharmaceutics |
PublicationYear | 2021 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref6/cit6 ref10/cit10 ref3/cit3 ref11/cit11 ref12/cit12 ref15/cit15 ref16/cit16 ref13/cit13 ref14/cit14 ref8/cit8 ref5/cit5 ref2/cit2 ref4/cit4 ref1/cit1 van der Maaten L. (ref17/cit17) 2008; 9 ref7/cit7 |
References_xml | – ident: ref1/cit1 doi: 10.1038/s41573-019-0028-1 – ident: ref11/cit11 doi: 10.1021/acs.biochem.9b00367 – ident: ref7/cit7 doi: 10.1016/j.jpba.2020.113703 – volume: 9 start-page: 2579 year: 2008 ident: ref17/cit17 publication-title: J. Mach. Learn. Res. – ident: ref13/cit13 doi: 10.1002/bit.22702 – ident: ref3/cit3 doi: 10.1073/pnas.1616408114 – ident: ref14/cit14 doi: 10.1016/j.ejpb.2017.01.019 – ident: ref16/cit16 doi: 10.1093/toxsci/kfw121 – ident: ref6/cit6 doi: 10.1021/acs.molpharmaceut.9b00852 – ident: ref9/cit9 doi: 10.1371/journal.pone.0168453 – ident: ref5/cit5 doi: 10.1073/pnas.1810576116 – ident: ref12/cit12 doi: 10.1093/bioinformatics/btl117 – ident: ref10/cit10 doi: 10.1038/nbt1000 – ident: ref15/cit15 doi: 10.1016/j.molimm.2018.11.020 – ident: ref8/cit8 doi: 10.1007/s11095-008-9737-6 – ident: ref2/cit2 doi: 10.3389/fimmu.2016.00394 – ident: ref4/cit4 doi: 10.1080/19420862.2020.1743053 |
SSID | ssj0024523 |
Score | 2.3314774 |
Snippet | Methods to optimize the solution behavior of therapeutic proteins are frequently time-consuming, provide limited information, and often use milligram... |
SourceID | proquest pubmed crossref acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 4131 |
SubjectTerms | Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - therapeutic use Biological Products - chemistry Biological Products - therapeutic use Chemistry, Pharmaceutical - methods Humans Machine Learning Peptides - chemistry Protein Array Analysis - methods Protein Stability Single-Chain Antibodies - chemistry Single-Chain Antibodies - therapeutic use |
Title | Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions |
URI | http://dx.doi.org/10.1021/acs.molpharmaceut.1c00543 https://www.ncbi.nlm.nih.gov/pubmed/34658237 https://www.proquest.com/docview/2583321858 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ1bS8MwFIAPOkF88X6ZNyLInuxsmy5pH2U4hqAMnLC3kiYpiNrK0j3MX-9J2zmniPraJqFNz8n56LkBnAvtKo0k7WjkZSdQkXIiVypHBcJNXKpTtwqQvWP9h-Bm1BnN87i_evB971JI037JbeJp_Yu37UkLGnQZVnyGymx5qHs_L7DXKXu6IRpQJ6RhsApnvy5lTZM0i6bpB94s7U5vA4az7J0q3OSpPSmStnz7XszxP6-0Ces1h5KrSnC2YEln29AaVGOnF2Q4z8syF6RFBvMS19MdeH4wmuQpGdiYGKXJrQ3rE-OxmBqCFEx6whREZIrU2U72TCWDsj04mko789P65CorHpNcTUkPx9btxEg3t850qxS7MOxdD7t9p-7b4Ag8MQpHpQhFrmRKep4OXcV8jkYwkZ6gIUPiY4qJEO9zydI04VESRYHoqAhZQnPO6R40sjzTB0A0LeNQdUBDHbBUJlwpISLJtMeRW2gTUOpMXKudiUuPuu_F9uLCBsf1BjfBn33i-LUq5_GXSWczYYhR-axHRWQ6n5jYtzlrCEmdsAn7lZR8LEsDhDuf8sP_PuMRrPk2cKZMeDyGRjGe6BMknyI5LSX9HV0JBA0 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3Na9swFMAfawftLvtqu2WfKoye6tS2HMk-hrCQbW0JNIVCD0aWZBjb7BE5h-yv33uymyyFsnVXWRKy_KT3w-8L4IOyobFI0oFFXg4Sk5kgC7UJTKLCIuS2DFsH2XMxuUw-Xw2uOq9KioXBRTicyXkj_jq7QHRCbT9qij_t_vT2I028wbfgIUJJTNI9HF2s8-wNfGk3JAQepDxNduDwr1ORhtJuU0PdgZ1e_YyfwPVq4d7r5Ft_0RR9_etWTsf_e7On8LijUjZsxegZPLDVcziatn2Xx2y2jtJyx-yITdcJr5d78P3SWVaXbEoeMsayM3LyU_O5WjqGTMzGyjVMVYZ1sU90w7KpLxaOipNG_jE_G1bN16I2SzbGvl1xMTaqybROR2QfZuOPs9Ek6Ko4BArvjyYwJSJSqIXRUWTT0IhYokosdKR4KpD_hBEqxedSi7IsZFZkWaIGJkOysFJKfgDbVV3Zl8As916pNuGpTUSpC2mMUpkWNpJIMbwHtL95dwhd7u3rcZRT48YG590G9yC--dL5zza5x78MOryRiRyPItlXVGXrhctjimBDZBqkPXjRCstqWp4g6sVcvrrvGt_D7mR2dpqffjr_8hoexeRS40Mh38B2M1_Yt8hETfHOC_9vckYMbg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7aFEIvfbfZPhUoOcUb2_Ja9nHZ1qSvYOgGchOyJENpY4eV97D99Z2RlWxTKH1cZWmQRzOaD80L4LWysbGIpCOLeDnKTGmiMtYmMpmKm5jbNh4DZE_y49Ps_dnsLDy4US4MbsIhJeed-KTVF6YNFQaSIxo_7ykHNbz2ThNNmIPfhFvkviMJny8-b2vtzXx7N0QJPCp4ke3C_h9JkZXS7rqV-g309CaougvyavM-8uTrdD00U_39l7qO__939-BOQKdsPorTfbhhuwdwUI9zN4dsuc3WcofsgNXbwtebh_Dt1FnWt6ymSBlj2ScK9lOrldo4htiYVcoNTHWGhRwoumlZ7ZuGowGllT_RZ_Nu-NL0ZsMqnBuajLFFTy52UpVHsKzeLhfHUejmECm8R4bItAiVYp0bnSS2iE2eCjSNjU4UL3LEgbnJVYHfhc7bthFlU5aZmpkSEYYVQvDHsNP1nd0DZrmPTrUZL2yWt7oRxihV6twmAtEMnwDxWAZldNL72dNE0uA1BsvA4Amkl6ctL8YiH3-zaP9SLiSqJPlZVGf7tZMpZbIhdJoVE3gyCswVWZ4h5Eu5ePqve3wFu_WbSn58d_LhGdxOKbLGZ0Q-h51htbYvEBoNzUsv_z8A8lEO8Q |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Peptide+Microarrays+for+Fast+and+Informative+Profiling+of+Therapeutic+Antibody+Formulation+Conditions&rft.jtitle=Molecular+pharmaceutics&rft.au=Austerberry%2C+James&rft.au=Edwards%2C+John&rft.au=Eyes%2C+Tim&rft.au=Derrick%2C+Jeremy+P&rft.date=2021-11-01&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=18&rft.issue=11&rft.spage=4131&rft_id=info:doi/10.1021%2Facs.molpharmaceut.1c00543&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon |